Keros Therapeutics Inc (KROS NASDAQ) stock market data APIs
$13.7603
0.13(0.9%)
as of October 17, 2025
Try our APIs with
free plan!
Keros Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Prev. Close
13.7603
Open
13.8868
High
13.9781
Low
13.7088
52 wk Range
9.12-72.37
Market Cap
558 M
P/E Ratio
43.2188
Shares Outstanding
30 439 K
Revenue
233 M
EPS
-0.76
Beta
0.972
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Keros Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Keros Therapeutics Inc data using free add-ons & libraries
Get Keros Therapeutics Inc Fundamental Data
Keros Therapeutics Inc Fundamental data includes:
- Net Revenue: 233 M
- EBITDA: 1 672 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -1.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Keros Therapeutics Inc News
New
Keros Therapeutics to Buy Back Shares From Adar1 Capital, Pontifax for $181 Million
Keros Therapeutics (KROS) said Wednesday it has entered into share purchase agreements to buy back a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Keros Therapeutics To Buyback $181 Mln Of Shares From ADAR1, Pontifax; Plans $194 Mln Tender Offer
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Wednesday announced that it has entered into share purchase agreements to buy back all shares held by ADAR1 ...
Keros jumps on plan to return $375M in excess capital
Keros Therapeutics (NASDAQ:KROS [https://seekingalpha.com/symbol/KROS]) has announced agreements to repurchase all shares of its common stock beneficially owned by each of ADAR1 Capital Management and...
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
